A practical reference on CAS Registry Number: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-07 and is reviewed periodically as new material appears.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Miguel Angel Ondetti (May 14, 1930 – August 23, 2004) was an Argentine-born American chemist who first synthesized captopril, the first ACE inhibitor that was used to treat heart disease. With his co-worker, David Cushman, he won the 1999 Lasker Award, with David Cushman, for: "developing an innovative approach to drug design based on protein structure and using it to create the ACE inhibitors, powerful oral agents for the treatment of high blood pressure, heart failure, and diabetic kidney disease". Ondetti was born and raised in Buenos Aires and received a PhD in chemistry from the University of Buenos Aires, in his hometown, in 1957. In 1960 he moved to The Squibb Institute for Medical Research in New Jersey where he researched and developed Captopril in 1975.
== History == Norketamine was synthesized by Calvin Lee Stevens in the early 1960s, as part of his team's work on α-aminoketones at Wayne State University. While most research has historically focused on its precursor, researchers have taken notice of norketamine's putative effects. Beginning in the late 1990s, Danish researchers discovered its role as a NMDA receptor antagonist. Later research uncovered its use as an antinociceptive, or "painkiller." Following the 2019 approval of the ketamine enantiomer esketamine by the European Medicines Agency and FDA for use with treatment-resistant depression, researchers and pharmaceutical companies have sought other effective intermediates and metabolites of racemic ketamine. Much of the research examining the potential role of norketamine as a distinct anti-depressant to its precursor began in the mid-2010s. Rodent models have showcased that norketamine crosses the blood-brain barrier, though considerably less efficiently than ketamine. Accordingly, its antidepressant effects are less potent than enantiomers of ketamine, but appear to be as effective as esketamine in its potency and duration. Unlike esketamine, (S)-norketamine does not appear to significantly impact prepulse inhibition (reduction of the startle reflex) and as such appears to have significantly fewer psychotomimetic effects - which may indicate that it could be a safer alternative to ketamine for use as an antidepressant in humans.
General xenobiochemistry, including in vitro studies concerned with the metabolism, disposition and excretion of drugs, and other xenobiotics, as well as the structure, function and regulation of associated enzymes Clinical pharmacokinetics and metabolism, covering the pharmacokinetics and absorption, distribution, metabolism and excretion of drugs and other xenobiotics in man. Animal pharmacokinetics and metabolism, covering the pharmacokinetics, and absorption, distribution, metabolism and excretion of drugs and other xenobiotics in animals. Pharmacogenetics, defined as the identification and functional characterisation of polymorphic genes that encode xenobiotic metabolising enzymes and transporters that may result in altered enzymatic, cellular and clinical responses to xenobiotics. Molecular toxicology, concerning the mechanisms of toxicity and the study of toxicology of xenobiotics at the molecular level. Topics in xenobiochemistry, in the form of reviews and commentaries are primarily intended to be a critical analysis of the issue, wherein the author offers opinions on the relevance of data or of a particular experimental approach or methodology. According to the Journal Citation Reports, the journal received a 2014 impact factor of 2.199, ranking it 134th out of 254 journals in the category Pharmacology & Pharmacy and 50th out of 87 journals in the category Toxicology. The editor in chief is Costas Ioannides (University of Surrey).
Enobosarm reached phase 2 clinical trials for this indication, but development was discontinued due to lack of effectiveness in a phase 2 study. Subsequently, enobosarm was repurposed again for the treatment of androgen receptor-positive (AR+) estrogen receptor-positive (ER+) breast cancer. As of November 2023, it is in phase 3 clinical trials for the treatment of this type of breast cancer. Increases in lean body mass and muscle strength as a secondary benefit with enobosarm are also being evaluated in these women. These trials are notably employing several-fold higher doses of enobosarm than were assessed in the muscle wasting phase 3 trials (9 mg/day versus 3 mg/day, respectively). In January 2024, it was announced that enobosarm was being developed for prevention of muscle wasting and augmentation of fat loss in combination with glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide for weight loss. A phase 2b clinical trial for this indication with 3 to 6 mg/day enobosarm in sarcopenic obese or overweight elderly individuals is being prepared. According to GTx, the original developer of enobosarm, a total of 25 clinical studies have been carried out on more than 1,700 people involving doses from 1 to 100 mg as of 2020. However, enobosarm has not yet completed clinical development or been approved for any use.
Sources: en.wikipedia.org
=== Fungal aminopeptidases === Fungi, particularly species like Aspergillus oryzae and Aspergillus sojae, produce aminopeptidases that have applications in the food industry as debittering agents. These enzymes are also of interest for their potential biotechnological applications. For example, leucine aminopeptidase (LAP) from Aspergillus species has been found to be thermostable and could theoretically be used to control the degree of hydrolysis and flavor development in a wide range of substances.
Engines (includes all models from 1998 to 2003) 1.3 L B3-ME SOHC I4 1.5 L ZL-DE DOHC I4 1.5 L ZL-VE S-VT I4 1.6 L ZM-DE DOHC I4 1.8 L FP-DE DOHC I4 2.0 L FS, 130 hp (97 kW; 132 PS) / 135 lb⋅ft (183 N⋅m) 2.0 L FS-ZE (2001 Sport 20) 2.0 L RF Diesel
=== Leo Bloom === Leo Bloom (Sonny Poon Tip) is Jesse's wayward, estranged 19-year-old son. Jesse hires Gus to tutor Leo on his college admissions essays to Oxford and Cambridge despite Leo's disinterest in school, and Leo and Gus soon begin a sexual relationship. Over time, Gus helps Leo discover his academic ambitions, and Leo is grateful for the experience despite not being admitted to either of his choice schools. Gus later utilizes his connections at Oxford to land Leo an admission, and Jesse hires Gus as his assistant in return after Gus loses his government job.
However, its toxicity to microorganisms is not overtly observed since the free silver ion is found in low concentrations in wastewater treatment systems and the natural environment due to its complexation with ligands such as chloride, sulfide, and thiosulfate.
Simon enters the previously chained-up apartment and, after a long hallway where he hears a doctor describing an encounter with his patient and being attacked yet again, finds the fuses. While attempting to retrieve the fuses again to open a gate for a train, he enters another nightmare where he is chased through a maze by monsters hanging from the ceiling, escaping through a door that opens back up to a completely different hallway. After boarding the train, Simon is attacked by monsters yet again, and the train eventually crashes and derails, causing him to lose all of his belongings. As the train is about to fall off a cliff, Simon narrowly escapes and finds himself in a dark forest. Deep in the forest, Simon discovers an asylum as the doctor enters. Simon finds the doctor behind a gate where the doctor orders him to hand him a new gun in exchange for letting him pass. Simon can either oblige or refuse, but regardless, the doctor ends up betraying Simon and shoots him (with a greater penalty to maximum health if Simon complied). Simon eventually kills the doctor after a gunfight. Simon leaves the forest and rows a boat across a lake to his hometown. He finally reaches his house and expects his mother to be waiting for him, but the house is empty. He enters his bedroom and finds a book. Through a flashback, the player finds out that the entire story was a figment of Simon's imagination. After the car crash, Simon became reliant on a wheelchair. Depressed, his therapist (who was the doctor in the game) advised him to document his feelings in a book.
Sources: en.wikipedia.org
=== Elimination === A single dose of oral estradiol valerate is eliminated 54% in urine and 6% in feces. A substantial amount of estradiol is also excreted in bile. The urinary metabolites of estradiol are predominantly present in the form of estrogen conjugates, including glucuronides and, to a lesser extent, sulfates. The main metabolites of estradiol in urine are estrone glucuronide (13–30%), 2-hydroxyestrone (2.6–10.1%), unchanged estradiol (5.2–7.5%), estriol (2.0–5.9%), and 16α-hydroxyestrone (1.0–2.9%). Following an intravenous injection of labeled estradiol in women, almost 90% is excreted in urine and feces within 4 to 5 days. Enterohepatic recirculation causes a delay in excretion of estradiol.
=== Degradation === Catecholamines have a half-life of a few minutes when circulating in the blood. They can be degraded either by methylation by catechol-O-methyltransferases (COMT) or by deamination by monoamine oxidases (MAO). MAOIs bind to MAO, thereby preventing it from breaking down catecholamines and other monoamines.
in the usual case where there are no sources or sinks, that is, for perfectly conserved quantities like energy or charge. This continuity equation is manifestly ("obviously") Lorentz invariant. Examples of continuity equations often written in this form include electric charge conservation
== Types == The types of intrauterine devices available and the names they go by differ by location. The WHO ATC labels both copper and hormonal devices as IUDs. In the United Kingdom, there are more than 10 different types of copper IUDs available. In the United Kingdom, the term IUD refers only to these copper devices. Hormonal intrauterine contraception is labeled with the term intrauterine system (IUS). In the United States, there are two types available:
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.